Entity Type
Company
- Info
- Significant Ownership
- Insider Trading
- Financials
- Holders: AZN, AZN
Filer Snapshot
Review latest filings on this page
Open insider trading context
ASTRAZENECA PLC SEC EDGAR Filings
SEC filings, ownership reports, and insider transactions for CIK 0000901832.
Total Filings
1,981
Latest Filing
09 Apr 2026
Industry
Pharmaceutical Preparations
Save or continue research
Save this filer for return loops, then jump into the latest filing evidence.
Save this research page
Create a free account to save this filer and follow future SEC filing updates.
- Symbol
- AZN on NYSE
- Business address
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA
- Top holdings (Schedule 13D)
- CLLS and Innate Pharma SA
- Top holdings (Schedule 13G)
- MNPR and CDT
- State of incorporation
- United Kingdom
- Fiscal year end
- 31 December
- Former names
- ZENECA GROUP PLC (to 05 Feb 1999)
Quick Takeaways
- ASTRAZENECA PLC is an SEC filer tracked under CIK 0000901832.
- 1,981 filings are listed on this profile.
- Common form coverage includes 6-K, 25-NSE, 3 and more.
What Changed
- Latest filing: 6-K filed on 09 Apr 2026.
- Report period: 09 Apr 2026.
Why This Matters
- You can quote filing dates and form types directly from the SEC record on this page.
- Use this profile before deeper ownership or insider analysis to confirm filing history context.
Official SEC Source
Filer Overview
ASTRAZENECA PLC has filed 1,981 SEC EDGAR filings since 13 Mar 1995. Common forms include 6-K, 25-NSE, 3, CERT and more.
Latest Filings
Recent SEC filings for ASTRAZENECA PLC with direct links to document and filing folders.
| Form type | Document | Filing | Description | Filing date | Reporting date | File number(s) |
|---|---|---|---|---|---|---|
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 09 Apr 2026 | 09 Apr 2026 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 08 Apr 2026 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER | 02 Apr 2026 | 02 Apr 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS AND ADMISSION OF SHARES | 01 Apr 2026 | 01 Apr 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS | 31 Mar 2026 | 31 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS | 27 Mar 2026 | 27 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTIFICATION OF ADMISSION OF SHARES | 20 Mar 2026 | 20 Mar 2026 | 001-11960 |
| 3 | Open 3 document | View SEC filing for 3 | OWNERSHIP DOCUMENT | 19 Mar 2026 | 18 Mar 2026 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER | 16 Mar 2026 | 16 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 10 Mar 2026 | 10 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 10 Mar 2026 | 10 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2026 | 06 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2026 | 06 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2026 | 06 Mar 2026 | 001-11960 |
| CERT | Open CERT document | View SEC filing for CERT | NYSE CERTIFICATION | 04 Mar 2026 | 001-11960 | |
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | FORM 8-A12B | 03 Mar 2026 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 02 Mar 2026 | 02 Mar 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Mar 2026 | 02 Mar 2026 | 001-11960 |
| 424B2 | Open 424B2 document | Open XBRL data | View SEC filing for 424B2 | 424B2 | 27 Feb 2026 | 333-278067 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A $2BN BOND OFFERING | 26 Feb 2026 | 26 Feb 2026 | 001-11960 |
| FWP | Open FWP document | View SEC filing for FWP | FWP | 26 Feb 2026 | 333-278067 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 25 Feb 2026 | 25 Feb 2026 | 001-11960 |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 25 Feb 2026 | 333-278067 | |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 24 Feb 2026 | 001-11960 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 24 Feb 2026 | 31 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 24 Feb 2026 | 24 Feb 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANNUAL FINANCIAL REPORT | 24 Feb 2026 | 24 Feb 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 24 Feb 2026 | 24 Feb 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FIXED-DURATION CALQUENCE COMBO APPROVED IN US | 20 Feb 2026 | 20 Feb 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 10 Feb 2026 | 10 Feb 2026 | 001-11960 |
| SCHEDULE 13G/A | Open SCHEDULE 13G/A document | View SEC filing for SCHEDULE 13G/A | 06 Feb 2026 | |||
| SCHEDULE 13D/A | Open SCHEDULE 13D/A document | View SEC filing for SCHEDULE 13D/A | 06 Feb 2026 | |||
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATION | 03 Feb 2026 | 03 Feb 2026 | 001-11960 |
| S-8 | Open S-8 document | Open XBRL data | View SEC filing for S-8 | FORM S-8 | 02 Feb 2026 | 333-293157 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Feb 2026 | 02 Feb 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCER | 02 Feb 2026 | 02 Feb 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA BEGINS TRADING ON NYSE | 02 Feb 2026 | 02 Feb 2026 | 001-11960 |
| 25 | Open 25 document | View SEC filing for 25 | FORM 25 | 30 Jan 2026 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPC | 30 Jan 2026 | 30 Jan 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030 | 29 Jan 2026 | 29 Jan 2026 | 001-11960 |
| CERT | Open CERT document | View SEC filing for CERT | NYSE CERTIFICATION | 22 Jan 2026 | 001-11960 | |
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 22 Jan 2026 | 001-11960 | |
| CERT | Open CERT document | View SEC filing for CERT | NYSE CERTIFICATION | 22 Jan 2026 | 001-11960 | |
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 22 Jan 2026 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSE | 20 Jan 2026 | 20 Jan 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILON | 08 Jan 2026 | 08 Jan 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jan 2026 | 02 Jan 2026 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Dec 2025 | 22 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED BTD FOR POST-NEOADJUVANT EARLY BC | 22 Dec 2025 | 22 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON LATIFY PHASE III TRIAL OF CERALASERTIB | 22 Dec 2025 | 22 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Dec 2025 | 19 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SUBCUTANEOUS SAPHNELO APPROVED IN EU | 16 Dec 2025 | 16 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN US FOR 1L HER2+ METASTATIC BC | 16 Dec 2025 | 16 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 04 Dec 2025 | 04 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Dec 2025 | 01 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2025 | 01 Dec 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN US FOR EARLY GASTRIC CANCER | 26 Nov 2025 | 26 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA MANUFACTURING INVESTMENT IN MARYLAND | 24 Nov 2025 | 24 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE US | 20 Nov 2025 | 20 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 17 Nov 2025 | 17 Nov 2025 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 14 Nov 2025 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Nov 2025 | 14 Nov 2025 | 001-11960 |
| 144 | Open 144 document | View SEC filing for 144 | 12 Nov 2025 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Nov 2025 | 10 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 9M AND Q3 2025 RESULTS | 06 Nov 2025 | 06 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF GENERAL MEETING | 03 Nov 2025 | 03 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Nov 2025 | 03 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 03 Nov 2025 | 03 Nov 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 28 Oct 2025 | 28 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | KOSELUGO (SELUMETINIB) APPROVED IN THE EU | 28 Oct 2025 | 28 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZSPIRE APPROVED IN EU FOR CRSWNP | 22 Oct 2025 | 22 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA APPROVES TEZSPIRE IN CRSWNP | 20 Oct 2025 | 20 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POSITIVE CHMP OPINION FOR SUBCUTANEOUS SAPHNELO | 20 Oct 2025 | 20 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AGREEMENT WITH US GOVT TO LOWER MEDICINE PRICES | 14 Oct 2025 | 14 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BAXDROSTAT MET PRIMARY ENDPOINT IN BAX24 PH3 TRIAL | 07 Oct 2025 | 07 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DATROWAY IMPROVED OS AND PFS IN TROPION-BREAST02 | 06 Oct 2025 | 06 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Oct 2025 | 01 Oct 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU IMPROVED IDFS IN EARLY BC IN DB-05 | 29 Sep 2025 | 29 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN HARMONISES LISTING STRUCTURE | 29 Sep 2025 | 29 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 6-K | 29 Sep 2025 | 29 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Sep 2025 | 25 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | KOSELUGO RECOMMENDED FOR EU APPROVAL | 22 Sep 2025 | 22 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP | 22 Sep 2025 | 22 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC | 17 Sep 2025 | 17 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON RESOLUTE PHASE III TRIAL | 17 Sep 2025 | 17 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Sep 2025 | 02 Sep 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 28 Aug 2025 | 28 Aug 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 26 Aug 2025 | 26 Aug 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 21 Aug 2025 | 21 Aug 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 Aug 2025 | 18 Aug 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 15 Aug 2025 | 15 Aug 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 12 Aug 2025 | 12 Aug 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2025 | 01 Aug 2025 | 001-11960 |
| 6-K | Open 6-K document | Open XBRL data | View SEC filing for 6-K | FORM 6-K | 29 Jul 2025 | 30 Jun 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS | 24 Jul 2025 | 24 Jul 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PLANS TO INVEST $50BN IN THE US | 22 Jul 2025 | 22 Jul 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS | 16 Jul 2025 | 16 Jul 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL | 14 Jul 2025 | 14 Jul 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN THE EU FOR BLADDER CANCER | 07 Jul 2025 | 07 Jul 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2025 | 01 Jul 2025 | 001-11960 |
| 11-K | Open 11-K document | View SEC filing for 11-K | FORM 11-K | 26 Jun 2025 | 31 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER | 24 Jun 2025 | 24 Jun 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC | 13 Jun 2025 | 13 Jun 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2025 | 12 Jun 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL | 06 Jun 2025 | 06 Jun 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 02 Jun 2025 | 02 Jun 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jun 2025 | 02 Jun 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI RECOMMENDED IN EU FOR BLADDER CANCER | 27 May 2025 | 27 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 May 2025 | 23 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 21 May 2025 | 21 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ACQUISITION OF ESOBIOTEC COMPLETED | 20 May 2025 | 20 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED DFS IN EARLY BLADDER CANCER | 09 May 2025 | 09 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU IMPROVED PCR IN EARLY-STAGE BREAST CANCER | 07 May 2025 | 07 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE COMBINATION APPROVED IN EU FOR 1L MCL | 06 May 2025 | 06 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BREZTRI MET PRIMARY ENDPOINTS IN PH3 ASTHMA TRIALS | 02 May 2025 | 02 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 May 2025 | 01 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 May 2025 | 01 May 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL | 29 Apr 2025 | 29 Apr 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON CAPITELLO-280 PHASE III TRIAL | 29 Apr 2025 | 29 Apr 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 1ST QUARTER RESULTS | 29 Apr 2025 | 29 Apr 2025 | 001-11960 |
| SCHEDULE 13G/A | Open SCHEDULE 13G/A document | View SEC filing for SCHEDULE 13G/A | 23 Apr 2025 | 005-55247 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU COMBINATION IMPROVED PFS IN 1L HER2+ MBC | 22 Apr 2025 | 22 Apr 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 11 Apr 2025 | 11 Apr 2025 | 001-11960 |
| SCHEDULE 13G/A | Open SCHEDULE 13G/A document | View SEC filing for SCHEDULE 13G/A | 10 Apr 2025 | |||
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN EU FOR AEGEAN | 04 Apr 2025 | 04 Apr 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN EU IN POST-ET BREAST CANCER | 04 Apr 2025 | 04 Apr 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2025 | 01 Apr 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE RECOMMENDED FOR EU APPROVAL IN 1L MCL | 31 Mar 2025 | 31 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN THE US FOR BLADDER CANCER | 31 Mar 2025 | 31 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN INVESTS $2.5BN IN BEIJING R&D & MANUFACTURING | 21 Mar 2025 | 21 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENEBOPARATIDE PHASE III TRIAL MET PRIMARY ENDPOINT | 17 Mar 2025 | 17 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN EU FOR LIMITED-STAGE SCLC | 17 Mar 2025 | 17 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO ACQUIRE ESOBIOTEC | 17 Mar 2025 | 17 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 12 Mar 2025 | 12 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED EFS IN EARLY-STAGE GASTRIC CANCER | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 07 Mar 2025 | 07 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2025 | 06 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 05 Mar 2025 | 05 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Mar 2025 | 03 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR AEGEAN | 03 Mar 2025 | 03 Mar 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU RECOMMENDED IN EU IN POST-ET BREAST CANCER | 28 Feb 2025 | 28 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CAMIZESTRANT IMPROVED PFS IN 1L HR+ BREAST CANCER | 26 Feb 2025 | 26 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 19 Feb 2025 | 19 Feb 2025 | 001-11960 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 18 Feb 2025 | 001-11960 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | FORM 20-F | 18 Feb 2025 | 31 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANNUAL FINANCIAL REPORT | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 18 Feb 2025 | 18 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 06 Feb 2025 | 06 Feb 2025 | 001-11960 |
| EFFECT | Open EFFECT document | View SEC filing for EFFECT | 05 Feb 2025 | 333-284374 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Feb 2025 | 03 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL FOR LS-SCLC | 03 Feb 2025 | 03 Feb 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN US FOR BREAST CANCER POST ET | 28 Jan 2025 | 28 Jan 2025 | 001-11960 |
| SCHEDULE 13D/A | Open SCHEDULE 13D/A document | View SEC filing for SCHEDULE 13D/A | 24 Jan 2025 | |||
| F-6 | Open F-6 document | View SEC filing for F-6 | 21 Jan 2025 | 333-284374 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DATO-DXD APPROVED IN US FOR HR+ BREAST CANCER | 21 Jan 2025 | 21 Jan 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE COMBINATION APPROVED IN US FOR 1L MCL | 17 Jan 2025 | 17 Jan 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jan 2025 | 02 Jan 2025 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DATO-DXD NSQ NSCLC APPLICATION WITHDRAWN IN EU | 26 Dec 2024 | 26 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO APPROVED IN EU BASED ON LAURA TRIAL | 23 Dec 2024 | 23 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 16 Dec 2024 | 16 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN US FOR LIMITED-STAGE SCLC | 05 Dec 2024 | 05 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA APPOINTS ISKRA REIC EVP INTERNATIONAL | 04 Dec 2024 | 04 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 02 Dec 2024 | 02 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Dec 2024 | 02 Dec 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRUQAP IMPROVED RPFS IN ADVANCED PROSTATE CANCER | 25 Nov 2024 | 25 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Nov 2024 | 20 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA | 18 Nov 2024 | 18 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Nov 2024 | 15 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Nov 2024 | 15 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Nov 2024 | 13 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA INVESTS $3.5 BILLION IN US | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | KOMET PHASE III TRIAL MET PRIMARY ENDPOINT | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 9M AND Q3 2024 RESULTS | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DATO-DXD NEW BLA SUBMITTED, NSQ BLA WITHDRAWN | 12 Nov 2024 | 12 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZSPIRE NASAL POLYPS TRIAL MET PRIMARY ENDPOINTS | 08 Nov 2024 | 08 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2024 | 01 Nov 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN CHINA PRESIDENT UNDER INVESTIGATION | 30 Oct 2024 | 30 Oct 2024 | 001-11960 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 28 Oct 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 21 Oct 2024 | 21 Oct 2024 | 001-11960 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 11 Oct 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA LICENSES LIPID LOWERING LP(A) ASSET | 07 Oct 2024 | 07 Oct 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Oct 2024 | 01 Oct 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO US APPROVAL IN UNRESECTABLE LUNG CANCER | 26 Sep 2024 | 26 Sep 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FASENRA RECOMMENDED FOR EU APPROVAL IN EGPA | 23 Sep 2024 | 23 Sep 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL OS RESULTS REPORTED FOR TROPION - BREAST01 | 23 Sep 2024 | 23 Sep 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FLUMIST APPROVED FOR SELF-ADMINISTRATION IN US | 20 Sep 2024 | 20 Sep 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FASENRA EGPA US FDA APPROVAL | 18 Sep 2024 | 18 Sep 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Sep 2024 | 13 Sep 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Sep 2024 | 02 Sep 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN US FOR RESECTABLE LUNG CANCER | 16 Aug 2024 | 16 Aug 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2024 | 01 Aug 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A EUR1.4BN BOND OFFERING | 30 Jul 2024 | 30 Jul 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE FIXED-DURATION COMBO IMPROVED 1L CLL PFS | 29 Jul 2024 | 29 Jul 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ODAC REVIEWED IMFINZI IN RESECTABLE LUNG CANCER | 26 Jul 2024 | 26 Jul 2024 | 001-11960 |
| 6-K | Open 6-K document | Open XBRL data | View SEC filing for 6-K | FORM 6K | 25 Jul 2024 | 30 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ACQUISITION OF AMOLYT PHARMA COMPLETED | 15 Jul 2024 | 15 Jul 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2024 | 01 Jul 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA & IMFINZI POSITIVE CHMP IN ENDOMETRIAL | 01 Jul 2024 | 01 Jul 2024 | 001-11960 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT | 26 Jun 2024 | 31 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON IMFINZI ADJUVANT BR.31 TRIAL | 25 Jun 2024 | 25 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED EFS AND OS IN BLADDER CANCER | 25 Jun 2024 | 25 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON CAPITELLO-290 PHASE III TRIAL | 18 Jun 2024 | 18 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN THE US FOR ENDOMETRIAL CANCER | 17 Jun 2024 | 17 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Jun 2024 | 12 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 04 Jun 2024 | 04 Jun 2024 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 04 Jun 2024 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 03 Jun 2024 | 03 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Jun 2024 | 03 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU | 03 Jun 2024 | 03 Jun 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER | 28 May 2024 | 28 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030 | 21 May 2024 | 21 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE | 20 May 2024 | 20 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT | 16 May 2024 | 16 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 May 2024 | 15 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT | 07 May 2024 | 07 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL | 02 May 2024 | 02 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 May 2024 | 01 May 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL | 29 Apr 2024 | 29 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW | 29 Apr 2024 | 29 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 1ST QUARTER RESULTS | 25 Apr 2024 | 25 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 11 Apr 2024 | 11 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% | 11 Apr 2024 | 11 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS | 08 Apr 2024 | 08 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC | 05 Apr 2024 | 05 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Apr 2024 | 02 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | VOYDEYA APPROVED IN US | 02 Apr 2024 | 02 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER | 02 Apr 2024 | 02 Apr 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS APPROVED IN THE US FOR NMOSD | 25 Mar 2024 | 25 Mar 2024 | 001-11960 |
| DFAN14A | Open DFAN14A document | View SEC filing for DFAN14A | DFAN14A | 19 Mar 2024 | ||
| F-3ASR | Open F-3ASR document | View SEC filing for F-3ASR | F-3ASR | 19 Mar 2024 | 333-278067 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 19 Mar 2024 | 19 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO ACQUIRE AMOLYT | 14 Mar 2024 | 14 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Mar 2024 | 12 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 07 Mar 2024 | 07 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 07 Mar 2024 | 07 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2024 | 06 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 Mar 2024 | 06 Mar 2024 | 001-11960 |
| CERT | Open CERT document | View SEC filing for CERT | 06 Mar 2024 | 001-11960 | ||
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 05 Mar 2024 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC | 04 Mar 2024 | 04 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Mar 2024 | 01 Mar 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 26 Feb 2024 | 26 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | VOYDEYA RECOMMENDED FOR EU APPROVAL | 26 Feb 2024 | 26 Feb 2024 | 001-11960 |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 23 Feb 2024 | 333-256406 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A $5BN BOND OFFERING | 22 Feb 2024 | 22 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 22 Feb 2024 | 22 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 22 Feb 2024 | 22 Feb 2024 | 001-11960 |
| FWP | Open FWP document | View SEC filing for FWP | FWP | 22 Feb 2024 | 333-256406 | |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 21 Feb 2024 | ||
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 21 Feb 2024 | 333-256406 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 21 Feb 2024 | 21 Feb 2024 | 001-11960 |
| S-8 | Open S-8 document | View SEC filing for S-8 | FORM S-8 | 20 Feb 2024 | 333-277197 | |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 20 Feb 2024 | 001-11960 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | FORM 20-F | 20 Feb 2024 | 31 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANNUAL FINANCIAL REPORT | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 20 Feb 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | 20 Feb 2024 | 20 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | 20 Feb 2024 | 19 Feb 2024 | 001-11960 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 15 Feb 2024 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SC 13G/A | 12 Feb 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 08 Feb 2024 | 08 Feb 2024 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2024 | 01 Feb 2024 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | 24 Jan 2024 | 005-55247 | ||
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 19 Jan 2024 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 19 Jan 2024 | 19 Jan 2024 | 001-11960 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 11 Jan 2024 | ||
| CORRESP | Open CORRESP document | View SEC filing for CORRESP | 10 Jan 2024 | |||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jan 2024 | 02 Jan 2024 | 001-11960 |
| SC TO-T | Open SC TO-T document | View SEC filing for SC TO-T | SC TO-T | 27 Dec 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ACQUIRES GRACELL | 27 Dec 2023 | 27 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 26 Dec 2023 | 26 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL | 22 Dec 2023 | 22 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 14 Dec 2023 | 14 Dec 2023 | 001-11960 |
| SC TO-C | Open SC TO-C document | View SEC filing for SC TO-C | SC TO-C | 12 Dec 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 12 Dec 2023 | 12 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO ACQUIRE ICOSAVAX | 12 Dec 2023 | 12 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Dec 2023 | 01 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2023 | 01 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | 01 Dec 2023 | 01 Dec 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Nov 2023 | 24 Nov 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | 17 Nov 2023 | 17 Nov 2023 | 001-11960 |
| SC 13D/A | Open SC 13D/A document | View SEC filing for SC 13D/A | SC 13D/A | 16 Nov 2023 | ||
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 14 Nov 2023 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | 14 Nov 2023 | 14 Nov 2023 | 001-11960 |
| 144 | Open 144 document | View SEC filing for 144 | 13 Nov 2023 | 001-11960 | ||
| SC 13D | Open SC 13D document | View SEC filing for SC 13D | SC 13D | 09 Nov 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 09 Nov 2023 | 09 Nov 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | 09 Nov 2023 | 09 Nov 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | 09 Nov 2023 | 09 Nov 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 9M AND Q3 2023 RESULTS | 09 Nov 2023 | 02 Nov 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2023 | 01 Nov 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | 01 Nov 2023 | 01 Nov 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | 03 Oct 2023 | 03 Oct 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Oct 2023 | 02 Oct 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DATO-DXD IMPROVED PFS IN BREAST CANCER | 25 Sep 2023 | 22 Sep 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | 20 Sep 2023 | 20 Sep 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | 15 Sep 2023 | 15 Sep 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT | 11 Sep 2023 | 11 Sep 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD | 06 Sep 2023 | 06 Sep 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Sep 2023 | 01 Sep 2023 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 16 Aug 2023 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2023 | 01 Aug 2023 | 001-11960 |
| 6-K | Open 6-K document | Open XBRL data | View SEC filing for 6-K | FORM 6K | 28 Jul 2023 | 30 Jun 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER | 28 Jul 2023 | 28 Jul 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION | 17 Jul 2023 | 17 Jul 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Jul 2023 | 03 Jul 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER | 03 Jul 2023 | 03 Jul 2023 | 001-11960 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT | 28 Jun 2023 | 31 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION | 09 Jun 2023 | 09 Jun 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS | 09 Jun 2023 | 09 Jun 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS | 02 Jun 2023 | 02 Jun 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Jun 2023 | 01 Jun 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jun 2023 | 01 Jun 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER | 01 Jun 2023 | 01 Jun 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER | 26 May 2023 | 26 May 2023 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 25 May 2023 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 22 May 2023 | 22 May 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER | 17 May 2023 | 17 May 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 May 2023 | 09 May 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA EXTENDED IN THE US FOR HEART FAILURE | 09 May 2023 | 09 May 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 May 2023 | 02 May 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ODAC VOTE ON LYNPARZA COMBO IN PROSTATE CANCER | 02 May 2023 | 02 May 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 02 May 2023 | 02 May 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 1ST QUARTER RESULTS | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGES | 27 Apr 2023 | 27 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 26 Apr 2023 | 26 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE TO ARRANGEMENTS WITH SOBI AND SANOFI | 11 Apr 2023 | 11 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA + IMFINZI MET ENDPOINT IN OVARIAN CANCER | 05 Apr 2023 | 05 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Apr 2023 | 03 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS RECOMMENDED FOR NMOSD EU APPROVAL | 03 Apr 2023 | 03 Apr 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA COMPLETES KYM AGREEMENT FOR CMG901 | 30 Mar 2023 | 30 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 27 Mar 2023 | 27 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 22 Mar 2023 | 22 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 22 Mar 2023 | 22 Mar 2023 | 001-11960 |
| CERT | Open CERT document | View SEC filing for CERT | 15 Mar 2023 | 001-11960 | ||
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 13 Mar 2023 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER | 09 Mar 2023 | 09 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Mar 2023 | 08 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 Mar 2023 | 08 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU DESTINY-PANTUMOR02 SHOWS POSITIVE RESULTS | 06 Mar 2023 | 06 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 03 Mar 2023 | 03 Mar 2023 | 001-11960 |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 02 Mar 2023 | 333-256406 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Mar 2023 | 01 Mar 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A $2.25BN BOND OFFERING | 01 Mar 2023 | 01 Mar 2023 | 001-11960 |
| FWP | Open FWP document | View SEC filing for FWP | FWP | 01 Mar 2023 | 333-256406 | |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 28 Feb 2023 | 333-256406 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A EUR1.5BN BOND OFFERING | 24 Feb 2023 | 24 Feb 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ACQUIRES CINCOR FOR CARDIORENAL ASSET | 24 Feb 2023 | 24 Feb 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 24 Feb 2023 | 24 Feb 2023 | 001-11960 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 24 Feb 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ENTERS AGREEMENT WITH KYM FOR CMG901 | 23 Feb 2023 | 23 Feb 2023 | 001-11960 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T | 23 Feb 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 22 Feb 2023 | 22 Feb 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 21 Feb 2023 | 21 Feb 2023 | 001-11960 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 21 Feb 2023 | 001-11960 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | FORM 20-F | 21 Feb 2023 | 31 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANNUAL FINANCIAL REPORT | 21 Feb 2023 | 21 Feb 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2023 | 13 Feb 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 13 Feb 2023 | 13 Feb 2023 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SC 13G/A | 10 Feb 2023 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SC 13G/A | 10 Feb 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FINAL RESULTS | 09 Feb 2023 | 09 Feb 2023 | 001-11960 |
| SC TO-T/A | Open SC TO-T/A document | View SEC filing for SC TO-T/A | SC TO-T/A | 03 Feb 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2023 | 01 Feb 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON EVUSHELD US EUA | 26 Jan 2023 | 26 Jan 2023 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | 24 Jan 2023 | 005-55247 | ||
| SC TO-T | Open SC TO-T document | View SEC filing for SC TO-T | SC TO-T | 23 Jan 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ACQUISITION OF NEOGENE THERAPEUTICS COMPLETED | 17 Jan 2023 | 17 Jan 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AIRSUPRA (PT027) APPROVED IN US FOR ASTHMA | 11 Jan 2023 | 11 Jan 2023 | 001-11960 |
| SC TO-C | Open SC TO-C document | View SEC filing for SC TO-C | SC TO-C | 09 Jan 2023 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ACQUIRE CINCOR FOR CARDIORENAL ASSET | 09 Jan 2023 | 09 Jan 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Jan 2023 | 03 Jan 2023 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 30 Dec 2022 | 30 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL | 28 Dec 2022 | 28 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS | 28 Dec 2022 | 28 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER | 21 Dec 2022 | 21 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN EU FOR PROSTATE CANCER | 21 Dec 2022 | 21 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR PATIENTS WITH HER2-LOW ME | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN THE EU FOR PATIENTS WITH PREVIOUSLY TREATED HER2-POSITIVE AD | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI PLUS IMJUDO RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR THE TREATMENT | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON PEARL PHASE III TRIAL OF IMFINZI MONOTHERAPY IN STAGE IV NON-SMALL CEL | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA CHMP OPINION FOR SYMPTOMATIC CHRONIC HF | 19 Dec 2022 | 19 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON US REVIEW OF LYNPARZA PROPEL SNDA | 15 Dec 2022 | 15 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CAPIVASERTIB PFS IN HR-POSITIVE BREAST CANCER | 08 Dec 2022 | 08 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2022 | 01 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Dec 2022 | 01 Dec 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ANNOUNCES SALE OF WEST CHESTER SITE | 30 Nov 2022 | 30 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO ACQUIRE NEOGENE THERAPEUTICS | 29 Nov 2022 | 29 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 23 Nov 2022 | 23 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU RECOMMENDED FOR EU APPROVAL IN GASTRIC | 14 Nov 2022 | 14 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI RECOMMENDED FOR APPROVAL IN THE EU FOR BTC | 14 Nov 2022 | 14 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA COMBO RECOMMENDED IN THE EU FOR MCRPC | 14 Nov 2022 | 14 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI + IMJUDO APPROVED IN US FOR LUNG CANCER | 14 Nov 2022 | 11 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | YTD AND Q3 2022 RESULTS | 10 Nov 2022 | 10 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA ADVISORY COMMITTEE RECOMMENDS PT027 IN ASTHMA | 09 Nov 2022 | 09 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEYFORTUS (NIRSEVIMAB) APPROVED IN EU | 04 Nov 2022 | 04 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2022 | 01 Nov 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CAPIVASERTIB PHASE III TRIAL MET PRIMARY ENDPOINTS | 26 Oct 2022 | 26 Oct 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON MESSINA PHASE III TRIAL | 25 Oct 2022 | 25 Oct 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI + IMJUDO APPROVED IN ADVANCED LIVER CANCER | 24 Oct 2022 | 24 Oct 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Oct 2022 | 03 Oct 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGES | 30 Sep 2022 | 30 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | KOSELUGO APPROVED IN JAPAN FOR NF1 | 27 Sep 2022 | 27 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZSPIRE APPROVED IN JAPAN FOR SEVERE ASTHMA | 27 Sep 2022 | 27 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS APPROVED IN EU FOR GMG | 23 Sep 2022 | 23 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN CHINA FOR OVARIAN CANCER | 22 Sep 2022 | 22 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZSPIRE APPROVED IN THE EU FOR SEVERE ASTHMA | 21 Sep 2022 | 21 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EVUSHELD APPROVED IN EU FOR COVID-19 TREATMENT | 20 Sep 2022 | 20 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DANICOPAN PHASE III TRIAL MET PRIMARY ENDPOINT | 16 Sep 2022 | 16 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NIRSEVIMAB RECOMMENDED FOR APPROVAL IN EU BY CHMP | 16 Sep 2022 | 16 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EVUSHELD POSITIVE CHMP OPINION IN EU | 16 Sep 2022 | 16 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN CHINA FOR CKD | 06 Sep 2022 | 06 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN US FOR BILIARY TRACT CANCER | 06 Sep 2022 | 06 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Sep 2022 | 01 Sep 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EVUSHELD APPROVED FOR COVID-19 IN JAPAN | 30 Aug 2022 | 30 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA REDUCED RISK OF CV DEATH OR WORSENING HF | 30 Aug 2022 | 30 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA SHOWS CV MORTALITY BENEFIT ACROSS EF RANGE | 30 Aug 2022 | 30 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS APPROVED IN JAPAN FOR GMG | 25 Aug 2022 | 25 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO APPROVED IN JAPAN FOR EARLY LUNG CANCER | 25 Aug 2022 | 25 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN JAPAN FOR EARLY BREAST CANCER | 25 Aug 2022 | 25 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR PROPEL | 16 Aug 2022 | 16 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 | 15 Aug 2022 | 15 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN US FOR HER2-MUTANT NSCLC | 12 Aug 2022 | 12 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ACQUISITION OF TENEOTWO COMPLETED | 11 Aug 2022 | 11 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN THE US FOR HER2-LOW MBC | 08 Aug 2022 | 08 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN EU FOR EARLY BREAST CANCER | 04 Aug 2022 | 04 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Aug 2022 | 01 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2022 | 01 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Aug 2022 | 01 Aug 2022 | 001-11960 |
| 6-K | Open 6-K document | Open XBRL data | View SEC filing for 6-K | FORM 6-K | 29 Jul 2022 | 30 Jun 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHAIR SUCCESSION | 29 Jul 2022 | 29 Jul 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZSPIRE RECOMMENDED FOR EU APPROVAL IN ASTHMA | 25 Jul 2022 | 25 Jul 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS RECOMMENDED FOR EU APPROVAL FOR GMG | 25 Jul 2022 | 25 Jul 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR HER2-LOW MBC | 25 Jul 2022 | 25 Jul 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN EU FOR HER2-POSITIVE MBC | 19 Jul 2022 | 19 Jul 2022 | 001-11960 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | 08 Jul 2022 | 005-55247 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO ACQUIRE TENEOTWO AND T CELL ENGAGER | 05 Jul 2022 | 05 Jul 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2022 | 01 Jul 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER | 30 Jun 2022 | 30 Jun 2022 | 001-11960 |
| 11-K | Open 11-K document | View SEC filing for 11-K | ANNUAL REPORT | 29 Jun 2022 | 31 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL | 27 Jun 2022 | 27 Jun 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA RECOMMENDED IN EU FOR EARLY BREAST CANCER | 27 Jun 2022 | 27 Jun 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EPLONTERSEN PH III TRIAL MET CO-PRIMARY ENDPOINTS | 21 Jun 2022 | 21 Jun 2022 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 10 Jun 2022 | 001-11960 | ||
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 09 Jun 2022 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU EFFICACY RESULTS IN HER2-LOW BREAST CANCER | 06 Jun 2022 | 06 Jun 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Jun 2022 | 01 Jun 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jun 2022 | 01 Jun 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 May 2022 | 20 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | APPOINTMENT OF JOINT CORPORATE BROKERS | 09 May 2022 | 09 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 06 May 2022 | 06 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN US FOR 2L HER2+ BREAST CANCER | 05 May 2022 | 05 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA HFPEF PHASE III TRIAL MET PRIMARY ENDPOINT | 05 May 2022 | 05 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS NMOSD PH. III TRIAL MET PRIMARY ENDPOINT | 05 May 2022 | 05 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC | 04 May 2022 | 04 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 May 2022 | 03 May 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 29 Apr 2022 | 29 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PLANS NEW R&D CENTRE IN MASSACHUSETTS | 29 Apr 2022 | 29 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FIRST QUARTER 2022 RESULTS | 29 Apr 2022 | 29 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS APPROVED IN THE US FOR ADULTS WITH GMG | 28 Apr 2022 | 28 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED BTD FOR HER2-LOW BREAST CANCER | 27 Apr 2022 | 27 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO | 25 Apr 2022 | 25 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC | 19 Apr 2022 | 19 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2022 | 01 Apr 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ONDEXXYA APPROVED IN JAPAN FOR FXAI REVERSAL | 29 Mar 2022 | 29 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EVUSHELD APPROVED IN THE EU FOR COVID-19 | 28 Mar 2022 | 28 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Mar 2022 | 25 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EVUSHELD POSITIVE EU CHMP OPINION | 24 Mar 2022 | 24 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON CALLA PHASE III TRIAL OF CONCURRENT USE OF IMFINZI AND CHEMORADIOTHERA | 24 Mar 2022 | 24 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 23 Mar 2022 | 23 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 23 Mar 2022 | 23 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SETTLEMENT OF PATENT LITIGATION FOR ULTOMIRIS | 17 Mar 2022 | 17 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN US FOR EARLY BREAST CANCER | 14 Mar 2022 | 14 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON US REVIEW OF FASENRA IN NASAL POLYPS | 14 Mar 2022 | 14 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Mar 2022 | 09 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 07 Mar 2022 | 07 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 Mar 2022 | 01 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Mar 2022 | 01 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006 | 01 Mar 2022 | 01 Mar 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 23 Feb 2022 | 23 Feb 2022 | 001-11960 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 22 Feb 2022 | 001-11960 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | FORM 20F | 22 Feb 2022 | 31 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHAIR SUCCESSION PLANNING UPDATE AND ANNUAL REPORT | 22 Feb 2022 | 22 Feb 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU IMPROVES PFS AND OS IN HER2-LOW BC | 22 Feb 2022 | 22 Feb 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SAPHNELO APPROVED IN EU FOR SLE | 16 Feb 2022 | 16 Feb 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA COMBO DELAYS PROGRESSION RISK IN PROSTATE | 15 Feb 2022 | 15 Feb 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 11 Feb 2022 | 11 Feb 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: FULL YEAR AND Q4 2021 RESULTS | 10 Feb 2022 | 10 Feb 2022 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | 07 Feb 2022 | 005-55247 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SEC SCHEDULE 13G | 04 Feb 2022 | 005-55247 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2022 | 01 Feb 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVES SURVIVAL IN BILIARY TRACT CANCER | 19 Jan 2022 | 19 Jan 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI COMBO SHOWS UNPRECEDENTED SURVIVAL IN HCC | 19 Jan 2022 | 19 Jan 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED PRIORITY REVIEW FOR BREAST CANCER | 18 Jan 2022 | 18 Jan 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AND NEURIMMUNE SIGN DEAL FOR NI006 | 07 Jan 2022 | 07 Jan 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSFER OF RIGHTS TO EKLIRA, DUAKLIR COMPLETED | 05 Jan 2022 | 05 Jan 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 04 Jan 2022 | 04 Jan 2022 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL | 29 Dec 2021 | 29 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG | 21 Dec 2021 | 21 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA | 20 Dec 2021 | 20 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE | 20 Dec 2021 | 20 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Dec 2021 | 15 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EVUSHELD US FDA EUA | 09 Dec 2021 | 09 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSEN | 07 Dec 2021 | 07 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Dec 2021 | 01 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2021 | 01 Dec 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIA | 30 Nov 2021 | 30 Nov 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 15 Nov 2021 | 15 Nov 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: YEAR TO DATE AND Q3 2021 RESULTS | 12 Nov 2021 | 12 Nov 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2021 | 01 Nov 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIR | 01 Nov 2021 | 01 Nov 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCER | 25 Oct 2021 | 25 Oct 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFER | 18 Oct 2021 | 18 Oct 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCER | 15 Oct 2021 | 15 Oct 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTS | 12 Oct 2021 | 12 Oct 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED BTD FOR BREAST CANCER | 04 Oct 2021 | 04 Oct 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Oct 2021 | 01 Oct 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 30 Sep 2021 | 30 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCES | 29 Sep 2021 | 29 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SAPHNELO APPROVED IN JAPAN FOR SLE | 28 Sep 2021 | 28 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINT | 24 Sep 2021 | 24 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGE | 23 Sep 2021 | 23 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NEW SUSTAINABILITY COMMITTEE OF THE BOARD | 23 Sep 2021 | 23 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT | 21 Sep 2021 | 21 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72% | 20 Sep 2021 | 20 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDON | 09 Sep 2021 | 09 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFIC | 09 Sep 2021 | 09 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNH | 03 Sep 2021 | 03 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Sep 2021 | 01 Sep 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN JAPAN FOR CKD | 26 Aug 2021 | 26 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT | 26 Aug 2021 | 26 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON ULTOMIRIS PHASE III ALS TRIAL | 20 Aug 2021 | 20 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINT | 20 Aug 2021 | 20 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Aug 2021 | 16 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON US REVIEW OF ROXADUSTAT | 11 Aug 2021 | 11 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN THE EU FOR CKD | 09 Aug 2021 | 09 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINT | 09 Aug 2021 | 09 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Aug 2021 | 02 Aug 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SAPHNELO APPROVED IN THE US FOR SLE | 02 Aug 2021 | 02 Aug 2021 | 001-11960 |
| 6-K/A | Open 6-K/A document | Open XBRL data | View SEC filing for 6-K/A | FORM 6-K/A | 30 Jul 2021 | 30 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | Open XBRL data | View SEC filing for 6-K | FORM 6-K | 30 Jul 2021 | 30 Jun 2021 | 001-11960 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 27 Jul 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNH | 26 Jul 2021 | 26 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 22 Jul 2021 | 22 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ACQUISITION OF ALEXION COMPLETED | 21 Jul 2021 | 21 Jul 2021 | 001-11960 |
| F-6EF | Open F-6EF document | View SEC filing for F-6EF | REGISTRATION OF AMERICAN DEPOSITAR RECEIPT SHARES | 19 Jul 2021 | 333-258002 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLC | 19 Jul 2021 | 19 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTAT | 16 Jul 2021 | 16 Jul 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 14 Jul 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 14 Jul 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UK | 14 Jul 2021 | 14 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMA | 08 Jul 2021 | 08 Jul 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 06 Jul 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 06 Jul 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EU | 06 Jul 2021 | 06 Jul 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2021 | 01 Jul 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 30 Jun 2021 | ||
| 11-K | Open 11-K document | View SEC filing for 11-K | FORM 11-K | 29 Jun 2021 | 31 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKD | 28 Jun 2021 | 28 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILE | 28 Jun 2021 | 28 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCER | 24 Jun 2021 | 24 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ORPATHYS APPROVED IN CHINA FOR LUNG CANCER | 23 Jun 2021 | 23 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1 | 22 Jun 2021 | 22 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON AZD7442 STORM CHASER TRIAL | 15 Jun 2021 | 15 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIB | 07 Jun 2021 | 07 Jun 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 04 Jun 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 04 Jun 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCER | 04 Jun 2021 | 04 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICER | 04 Jun 2021 | 04 Jun 2021 | 001-11960 |
| CERT | Open CERT document | View SEC filing for CERT | 03 Jun 2021 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | PUBLICATION OF FINAL TERMS | 02 Jun 2021 | 02 Jun 2021 | 001-11960 |
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 01 Jun 2021 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Jun 2021 | 01 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jun 2021 | 01 Jun 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 28 May 2021 | 28 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAG | 28 May 2021 | 28 May 2021 | 001-11960 |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 27 May 2021 | 333-256406 | |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 27 May 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A EUR800M BOND OFFERING | 27 May 2021 | 27 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A $7BN BOND OFFERING | 26 May 2021 | 26 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 26 May 2021 | 26 May 2021 | 001-11960 |
| FWP | Open FWP document | View SEC filing for FWP | FWP | 26 May 2021 | 333-256406 | |
| FWP | Open FWP document | View SEC filing for FWP | FWP | 26 May 2021 | 333-256406 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUS | 25 May 2021 | 25 May 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 24 May 2021 | ||
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | 424B2 | 24 May 2021 | 333-256406 | |
| F-3ASR | Open F-3ASR document | View SEC filing for F-3ASR | F-3ASR | 24 May 2021 | 333-256406 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 24 May 2021 | 24 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPAN | 21 May 2021 | 21 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 18 May 2021 | 18 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 11 May 2021 | 11 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITION | 11 May 2021 | 11 May 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 07 May 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDON | 07 May 2021 | 07 May 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 06 May 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 05 May 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 04 May 2021 | 04 May 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA APPROVED IN THE US FOR CKD | 04 May 2021 | 04 May 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 30 Apr 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 30 Apr 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 30 Apr 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: FIRST QUARTER 2021 RESULTS | 30 Apr 2021 | 30 Apr 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 29 Apr 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT | 26 Apr 2021 | 26 Apr 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINION | 26 Apr 2021 | 26 Apr 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1 | 26 Apr 2021 | 26 Apr 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 16 Apr 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 16 Apr 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | US CLEARANCE OF PROPOSED ACQUISITION OF ALEXION | 16 Apr 2021 | 16 Apr 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCER | 14 Apr 2021 | 14 Apr 2021 | 001-11960 |
| 424B3 | Open 424B3 document | View SEC filing for 424B3 | 424B3 | 13 Apr 2021 | 333-253315 | |
| EFFECT | Open EFFECT document | View SEC filing for EFFECT | 12 Apr 2021 | 333-253315 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 12 Apr 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 12 Apr 2021 | 12 Apr 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CIRCULAR AND NOTICE OF GENERAL MEETING | 12 Apr 2021 | 12 Apr 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 12 Apr 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL | 12 Apr 2021 | 12 Apr 2021 | 001-11960 |
| F-4/A | Open F-4/A document | View SEC filing for F-4/A | F-4/A | 09 Apr 2021 | 333-253315 | |
| CORRESP | Open CORRESP document | View SEC filing for CORRESP | 08 Apr 2021 | |||
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 08 Apr 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 01 Apr 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 01 Apr 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 01 Apr 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2021 | 01 Apr 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 30 Mar 2021 | 30 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 30 Mar 2021 | 30 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 25 Mar 2021 | 25 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY | 25 Mar 2021 | 25 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINT | 22 Mar 2021 | 22 Mar 2021 | 001-11960 |
| 4 | Open 4 document | View SEC filing for 4 | 4 | 16 Mar 2021 | 15 Mar 2021 | 001-39067 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIVESTMENT OF VIELA SHAREHOLDING COMPLETED | 16 Mar 2021 | 16 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSES | 16 Mar 2021 | 16 Mar 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 12 Mar 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 09 Mar 2021 | 09 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DESIGNATION OF EU HOME MEMBER STATE FOR EU SECURITIES REGULATION PURPOSES | 04 Mar 2021 | 04 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US COURT DECISION FAVOURS SYMBICORT PATENTS | 03 Mar 2021 | 03 Mar 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FURTHER UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNE | 02 Mar 2021 | 02 Mar 2021 | 001-11960 |
| UPLOAD | Open UPLOAD document | View SEC filing for UPLOAD | 01 Mar 2021 | |||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRANSPARENCY DIRECTIVE VOTING RIGHTS AND CAPITAL | 01 Mar 2021 | 01 Mar 2021 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 26 Feb 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 25 Feb 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | VOLUNTARY WITHDRAWAL OF IMFINZI INDICATION IN ADVANCED BLADDER CANCER IN THE US | 22 Feb 2021 | 22 Feb 2021 | 001-11960 |
| F-4 | Open F-4 document | View SEC filing for F-4 | F-4 | 19 Feb 2021 | 333-253315 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA: IDMC RECOMMEND EARLY ANALYSIS OF OLYMPIA | 17 Feb 2021 | 17 Feb 2021 | 001-11960 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 16 Feb 2021 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 16 Feb 2021 | 16 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Feb 2021 | 16 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANNUAL FINANCIAL REPORT | 16 Feb 2021 | 16 Feb 2021 | 001-11960 |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 16 Feb 2021 | 31 Dec 2020 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 12 Feb 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 11 Feb 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 11 Feb 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 11 Feb 2021 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 11 Feb 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA NON-EXECUTIVE BOARD CHANGES | 11 Feb 2021 | 11 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: FULL-YEAR 2020 RESULTS | 11 Feb 2021 | 11 Feb 2021 | 001-11960 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 10 Feb 2021 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SC 13G/A | 10 Feb 2021 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIVESTMENT OF CRESTOR IN EUROPE COMPLETED | 10 Feb 2021 | 10 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON KESTREL PHASE III TRIAL FOR IMFINZI | 05 Feb 2021 | 05 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN CHINA FOR HEART FAILURE | 04 Feb 2021 | 04 Feb 2021 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SEC SCHEDULE 13G | 03 Feb 2021 | 005-55247 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2021 | 01 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AGREES TO DIVEST VIELA SHAREHOLDING | 01 Feb 2021 | 01 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | COVID-19 VACCINE AUTHORISED FOR USE BY THE EU | 01 Feb 2021 | 01 Feb 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | COVID-19 VACCINE RECEIVES POSITIVE OPINION IN EU | 29 Jan 2021 | 29 Jan 2021 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | 29 Jan 2021 | 005-55247 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING APPLICATION | 26 Jan 2021 | 26 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SYMBICORT APPROVED IN CHINA FOR MILD ASTHMA | 26 Jan 2021 | 26 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE APPROVED IN JAPAN FOR CLL | 25 Jan 2021 | 25 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE MET PRIMARY EFFICACY ENDPOINT IN HEAD-TO-HEAD TRIAL AGAINST IBRUTINIB | 25 Jan 2021 | 25 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN THE EU FOR BREAST CANCER | 20 Jan 2021 | 20 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU APPROVED IN THE US FOR GASTRIC CANCER | 19 Jan 2021 | 19 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN THE EU FOR LESS-FREQUENT, FIXED- DOSE USE IN UNRESECTABLE NO | 15 Jan 2021 | 15 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF PATIENTS WITH CHR | 06 Jan 2021 | 06 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 04 Jan 2021 | 04 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ATACAND DIVESTMENT TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES COMPLETED | 04 Jan 2021 | 04 Jan 2021 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA'S COVID-19 VACCINE AUTHORISED IN UK | 30 Dec 2020 | 30 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN JAPAN FOR THE TREATMENT OF ADVANCED OVARIAN, PROSTATE AND P | 29 Dec 2020 | 29 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO APPROVED IN THE US FOR THE ADJUVANT TREATMENT OF PATIENTS WITH EARLY-ST | 21 Dec 2020 | 21 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEAS | 21 Dec 2020 | 21 Dec 2020 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 18 Dec 2020 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 17 Dec 2020 | 17 Dec 2020 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 17 Dec 2020 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 16 Dec 2020 | 16 Dec 2020 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 15 Dec 2020 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI NEW DOSE RECEIVES POSITIVE EU CHMP OPINION | 15 Dec 2020 | 15 Dec 2020 | 001-11960 |
| 425 | Open 425 document | View SEC filing for 425 | 425 | 14 Dec 2020 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 14 Dec 2020 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 14 Dec 2020 | ||
| 425 | Open 425 document | View SEC filing for 425 | 425 | 14 Dec 2020 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TRASTUZUMAB DERUXTECAN POSITIVE CHMP | 14 Dec 2020 | 14 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRIXEO AEROSPHERE APPROVED IN THE EU FOR COPD | 14 Dec 2020 | 14 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO ACQUIRE ALEXION PHARMACEUTICALS INC | 14 Dec 2020 | 14 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Dec 2020 | 01 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Dec 2020 | 01 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE | 01 Dec 2020 | 01 Dec 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE | 30 Nov 2020 | 30 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZD1222 VACCINE EFFECTIVE AGAINST COVID-19 | 23 Nov 2020 | 23 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI NEW DOSING APPROVED IN THE US | 20 Nov 2020 | 20 Nov 2020 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 13 Nov 2020 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TEZEPELUMAB PHASE III TRIAL MET PRIMARY ENDPOINT | 10 Nov 2020 | 10 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE APPROVED IN THE EU FOR CLL | 09 Nov 2020 | 09 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BRILINTA APPROVED IN THE US IN STROKE | 06 Nov 2020 | 06 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: YEAR-TO-DATE AND Q3 2020 RESULTS | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN THE EU FOR HEART FAILURE | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN THE EU AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZAAPPROVED IN THE EU FOR THE TREATMENT OF BRCA- MUTATED METASTATIC CASTRAT | 05 Nov 2020 | 05 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Nov 2020 | 02 Nov 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ATACAND TO BE DIVESTED TO CHEPLAPHARM IN MORE THAN 70 COUNTRIES | 30 Oct 2020 | 30 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 29 Oct 2020 | 29 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED PRIORITY REVIEW IN THE US FOR THE TREATMENT OF HER2-POSITIVE MET | 28 Oct 2020 | 28 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA CARDIOVASCULAR OUTCOMES BENEFIT APPROVED IN CHINA | 28 Oct 2020 | 28 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO ADJUVANT LUNG CANCER US PRIORITY REVIEW | 20 Oct 2020 | 20 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA HF RECEIVES POSITIVE CHMP OPINION | 19 Oct 2020 | 19 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRIXEO AEROSPHERE RECEIVES POSITIVE CHMP OPINION | 19 Oct 2020 | 19 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | COVID-19 ANTIBODIES ADVANCE AND GET US FUNDING | 13 Oct 2020 | 13 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA GRANTED US BTD IN CHRONIC KIDNEY DISEASE | 02 Oct 2020 | 02 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Oct 2020 | 01 Oct 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 25 Sep 2020 | 25 Sep 2020 | 001-11960 |
| CERT | Open CERT document | View SEC filing for CERT | 24 Sep 2020 | 001-11960 | ||
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | 8-A12B | 24 Sep 2020 | 001-11960 | |
| 25 | Open 25 document | View SEC filing for 25 | 25 | 24 Sep 2020 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA RECOMMENDED FOR APPROVAL IN THE EU BY CHMP FOR BRCA-MUTATED METASTATIC | 21 Sep 2020 | 21 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZARECOMMENDED FOR APPROVAL IN EU BY CHMP AS 1ST-LINE MAINTENANCE TREATMENT | 21 Sep 2020 | 21 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO REDUCED THE RISK OF DISEASE RECURRENCE IN THE BRAIN BY 82% IN THE ADJUV | 21 Sep 2020 | 21 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO LIST US ADR EQUITY AND ALL US DEBT SECURITIES ON NASDAQ | 10 Sep 2020 | 10 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FASENRA MET BOTH CO-PRIMARY ENDPOINTS OF REDUCED NASAL POLYP SIZE AND BLOCKAGE I | 10 Sep 2020 | 10 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Sep 2020 | 01 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN EU FOR SMALL CELL LUNG CANCER | 01 Sep 2020 | 01 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA REDUCES CKD PROGRESSION AND RISK OF DEATH | 01 Sep 2020 | 01 Sep 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | PHASE I CLINICAL TRIAL INITIATED FOR MONOCLONAL ANTIBODY COMBINATION FOR THE PRE | 25 Aug 2020 | 25 Aug 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN JAPAN FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG C | 21 Aug 2020 | 21 Aug 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI GRANTED FDA PRIORITY REVIEW FOR LESS-FREQUENT, FIXED-DOSE USE | 18 Aug 2020 | 18 Aug 2020 | 001-11960 |
| CERT | Open CERT document | View SEC filing for CERT | NYSE CERTIFICATION | 12 Aug 2020 | 001-11960 | |
| 8-A12B | Open 8-A12B document | View SEC filing for 8-A12B | FORM 8-A12B | 06 Aug 2020 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORM 6-K | 06 Aug 2020 | 06 Aug 2020 | 001-11960 |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | FORM 424B2 | 05 Aug 2020 | 333-234586 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PRICES A $3BN BOND ISSUE | 04 Aug 2020 | 04 Aug 2020 | 001-11960 |
| FWP | Open FWP document | View SEC filing for FWP | FORM FWP | 04 Aug 2020 | 333-234586 | |
| S-8 | Open S-8 document | View SEC filing for S-8 | S-8 | 03 Aug 2020 | 333-240298 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Aug 2020 | 03 Aug 2020 | 001-11960 |
| FWP | Open FWP document | View SEC filing for FWP | FORM FWP | 03 Aug 2020 | 333-234586 | |
| 424B2 | Open 424B2 document | View SEC filing for 424B2 | FORM 424B2 | 03 Aug 2020 | 333-234586 | |
| 6-K/A | Open 6-K/A document | Open XBRL data | View SEC filing for 6-K/A | 6-K/A | 31 Jul 2020 | 30 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: H1 2020 RESULTS | 30 Jul 2020 | 30 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO US BTD FOR EGFRM ADJUVANT LUNG CANCER | 30 Jul 2020 | 30 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BOARD COMMITTEE CHANGES | 29 Jul 2020 | 29 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA DAPA-CKD TRIAL MET ALL ENDPOINTS | 28 Jul 2020 | 28 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI RECOMMENDED FOR EU APPROVAL IN SCLC | 27 Jul 2020 | 27 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE RECEIVES POSITIVE CHMP OPINION FOR CLL | 27 Jul 2020 | 27 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ENTERS COLLABORATION IN ONCOLOGY | 27 Jul 2020 | 27 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BREZTRI AEROSPHERE APPROVED IN THE US FOR THE MAINTENANCE TREATMENT OF COPD | 24 Jul 2020 | 24 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 22 Jul 2020 | 22 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 22 Jul 2020 | 22 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 21 Jul 2020 | 21 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 21 Jul 2020 | 21 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | COVID-19 VACCINE AZD1222 SHOWED ROBUST IMMUNE RESPONSES IN ALL PARTICIPANTS IN P | 20 Jul 2020 | 20 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 16 Jul 2020 | 16 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BRILINTA GRANTED US FDA PRIORITY REVIEW FOR STROKE | 09 Jul 2020 | 09 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN THE EU FOR BRCA- MUTATED METASTATIC PANCREATIC CANCER | 08 Jul 2020 | 08 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2020 | 01 Jul 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 30 Jun 2020 | 30 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR NEUROFIBROMATOSIS TYPE | 30 Jun 2020 | 30 Jun 2020 | 001-11960 |
| 11-K | Open 11-K document | View SEC filing for 11-K | 26 Jun 2020 | 31 Dec 2019 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 17 Jun 2020 | 17 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 17 Jun 2020 | 17 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO SUPPLY EUROPE WITH UP TO 400 MILLION DOSES OF OXFORD UNIVERSITY'S | 15 Jun 2020 | 15 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMTN PROGRAMME ROUTINE TECHNICAL UPDATE: PUBLICATION OF PROSPECTUS | 11 Jun 2020 | 11 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA RECOMMENDED FOR APPROVAL IN EU BY CHMP FOR BRCA-MUTATED METASTATIC PANC | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BRILINTA APPROVED IN THE US TO REDUCE THE RISK OF A FIRST HEART ATTACK OR STROKE | 01 Jun 2020 | 01 Jun 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTUSIGNIFICANTLY IMPROVED TUMOUR RESPONSE RATE AND OVERALL SURVIVAL IN HER2- | 29 May 2020 | 29 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI SHOWED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE | 29 May 2020 | 29 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATM | 29 May 2020 | 29 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 May 2020 | 26 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR GASTRIC CANCER | 22 May 2020 | 22 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ADVANCES RESPONSE TO GLOBAL COVID-19 CHALLENGE AS IT RECEIVES FIRST | 21 May 2020 | 21 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN THE US FOR HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT | 20 May 2020 | 20 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU US BREAKTHROUGH STATUS FOR LUNG CANCER | 18 May 2020 | 18 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEVESPI AEROSPHERE APPROVED IN CHINA FOR COPD | 18 May 2020 | 18 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU GRANTED BREAKTHROUGH THERAPY DESIGNATION IN THE US FOR HER2-POSITIVE MET | 11 May 2020 | 11 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM | 11 May 2020 | 11 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F | 11 May 2020 | 11 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H | 06 May 2020 | 06 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 May 2020 | 01 May 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 29 Apr 2020 | 29 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: FIRST-QUARTER 2020 RESULTS | 29 Apr 2020 | 29 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA DEMONSTRATED OVERALL SURVIVAL BENEFIT IN PHASE III PROFOUND TRIAL FOR B | 24 Apr 2020 | 24 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CHANGES TO ARRANGEMENTS FOR ANNUAL GENERAL MEETING | 17 Apr 2020 | 17 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | KOSELUGO (SELUMETINIB) APPROVED IN US FOR PAEDIATRIC PATIENTS WITH NEUROFIBROMAT | 14 Apr 2020 | 14 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO PHASE III ADAURA TRIAL WILL BE UNBLINDED EARLY AFTER OVERWHELMING EFFIC | 14 Apr 2020 | 14 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA DIVESTMENT OF MOVANTIK TO REDHILL BIOPHARMA COMPLETED | 02 Apr 2020 | 02 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2020 | 01 Apr 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 31 Mar 2020 | 31 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA PHASE III DAPA-CKD TRIAL WILL BE STOPPED EARLY AFTER OVERWHELMING EFFICA | 30 Mar 2020 | 30 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN THE US FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER | 30 Mar 2020 | 30 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 26 Mar 2020 | 26 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LOKELMA APPROVED IN JAPAN FOR THE TREATMENT OF HYPERKALAEMIA | 26 Mar 2020 | 26 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 20 Mar 2020 | 20 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA GRANTED ORPHAN DRUG DESIGNATION IN JAPAN FOR BRCA-MUTATED METASTATIC PA | 19 Mar 2020 | 19 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI CONFIRMED A SUSTAINED OVERALL SURVIVAL BENEFIT IN FINAL ANALYSIS OF THE | 17 Mar 2020 | 17 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 6-K | 12 Mar 2020 | 12 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 12 Mar 2020 | 12 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON PHASE III GY004 TRIAL FOR CEDIRANIB ADDED TO LYNPARZA IN PLATINUM-SENS | 12 Mar 2020 | 12 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 10 Mar 2020 | 10 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S | 06 Mar 2020 | 06 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 04 Mar 2020 | 04 Mar 2020 | 001-11960 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 03 Mar 2020 | 001-11960 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 03 Mar 2020 | 31 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANNUAL FINANCIAL REPORT | 03 Mar 2020 | 03 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Mar 2020 | 02 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA COMPLETES DIVESTMENT AGREEMENT WITH ATNAHS PHARMA FOR ESTABLISHED HY | 02 Mar 2020 | 02 Mar 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 27 Feb 2020 | 27 Feb 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA DIVESTS GLOBAL RIGHTS TO MOVANTIK | 25 Feb 2020 | 25 Feb 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 19 Feb 2020 | 19 Feb 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: FULL-YEAR AND Q4 2019 RESULTS | 14 Feb 2020 | 14 Feb 2020 | 001-11960 |
| 4 | Open 4 document | View SEC filing for 4 | 4 | 07 Feb 2020 | 19 Dec 2019 | 001-35112 |
| 3 | Open 3 document | View SEC filing for 3 | 3 | 07 Feb 2020 | 19 Dec 2019 | 001-35112 |
| SC 13D | Open SC 13D document | View SEC filing for SC 13D | SC 13D | 07 Feb 2020 | ||
| EFFECT | Open EFFECT document | View SEC filing for EFFECT | 06 Feb 2020 | 333-236014 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | 05 Feb 2020 | 005-55247 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Feb 2020 | 03 Feb 2020 | 001-11960 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 30 Jan 2020 | ||
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SEC SCHEDULE 13G | 27 Jan 2020 | 005-55247 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES | 27 Jan 2020 | 27 Jan 2020 | 001-11960 |
| F-6 | Open F-6 document | View SEC filing for F-6 | FORM F-6 | 22 Jan 2020 | 333-236014 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED | 21 Jan 2020 | 20 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN | 21 Jan 2020 | 20 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA | 13 Jan 2020 | 13 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA | 13 Jan 2020 | 13 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA | 06 Jan 2020 | 06 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED | 06 Jan 2020 | 06 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jan 2020 | 02 Jan 2020 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- | 30 Dec 2019 | 30 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP | 23 Dec 2019 | 23 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB | 23 Dec 2019 | 23 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO | 20 Dec 2019 | 20 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER | 17 Dec 2019 | 17 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA | 16 Dec 2019 | 16 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL | 12 Dec 2019 | 12 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE | 11 Dec 2019 | 11 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV | 05 Dec 2019 | 05 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADA | 03 Dec 2019 | 03 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 02 Dec 2019 | 02 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Dec 2019 | 02 Dec 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVE | 29 Nov 2019 | 29 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEM | 21 Nov 2019 | 21 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2D | 15 Nov 2019 | 15 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIB | 14 Nov 2019 | 14 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIE | 12 Nov 2019 | 12 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO I | 12 Nov 2019 | 12 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASE | 08 Nov 2019 | 08 Nov 2019 | 001-11960 |
| F-3ASR | Open F-3ASR document | View SEC filing for F-3ASR | FORM F-3ASR | 08 Nov 2019 | 333-234586 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LIN | 06 Nov 2019 | 06 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2019 | 01 Nov 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIA | 30 Oct 2019 | 30 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYED | 28 Oct 2019 | 28 Oct 2019 | 001-11960 |
| SC 13D | Open SC 13D document | View SEC filing for SC 13D | SC 13D | 25 Oct 2019 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTS | 24 Oct 2019 | 24 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILU | 21 Oct 2019 | 21 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WIT | 17 Oct 2019 | 17 Oct 2019 | 001-11960 |
| 4 | Open 4 document | View SEC filing for 4 | FORM 4 SUBMISSION | 09 Oct 2019 | 07 Oct 2019 | 001-39067 |
| 3/A | Open 3/A document | View SEC filing for 3/A | FORM 3/A SUBMISSION | 09 Oct 2019 | 02 Oct 2019 | 001-39067 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 04 Oct 2019 | 04 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 04 Oct 2019 | 04 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATION | 04 Oct 2019 | 04 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 03 Oct 2019 | 03 Oct 2019 | 001-11960 |
| 3 | Open 3 document | View SEC filing for 3 | FORM 3 SUBMISSION | 02 Oct 2019 | 02 Oct 2019 | 001-39067 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Oct 2019 | 01 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHAR | 01 Oct 2019 | 01 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON US REGULATORY REVIEW OF PT010 IN COPD | 01 Oct 2019 | 01 Oct 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN | 30 Sep 2019 | 30 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS | 30 Sep 2019 | 30 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CAN | 30 Sep 2019 | 30 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMP | 23 Sep 2019 | 23 Sep 2019 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 18 Sep 2019 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINA | 18 Sep 2019 | 18 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMP | 09 Sep 2019 | 09 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CE | 04 Sep 2019 | 04 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Sep 2019 | 03 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUC | 03 Sep 2019 | 03 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ART | 03 Sep 2019 | 03 Sep 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOS | 29 Aug 2019 | 29 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBS | 28 Aug 2019 | 28 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITIS | 28 Aug 2019 | 28 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPEND | 22 Aug 2019 | 22 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEW | 22 Aug 2019 | 22 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON THE PHASE III NEPTUNE TRIAL | 21 Aug 2019 | 21 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE III | 20 Aug 2019 | 20 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 19 Aug 2019 | 19 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATION | 14 Aug 2019 | 14 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINT | 14 Aug 2019 | 14 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVAL | 09 Aug 2019 | 09 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA PHASE III PROFOUND TRIAL IN HRR* | 07 Aug 2019 | 07 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETES | 05 Aug 2019 | 05 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Aug 2019 | 01 Aug 2019 | 001-11960 |
| 6-K | Open 6-K document | Open XBRL data | View SEC filing for 6-K | 6-K | 25 Jul 2019 | 30 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON US REGULATORY DECISION FOR FARXIGA | 15 Jul 2019 | 15 Jul 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCER | 12 Jul 2019 | 12 Jul 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELF | 01 Jul 2019 | 01 Jul 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Jul 2019 | 01 Jul 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA RECEIVES POSITIVE EU CHMP OPINION FOR | 01 Jul 2019 | 01 Jul 2019 | 001-11960 |
| 11-K | Open 11-K document | View SEC filing for 11-K | 27 Jun 2019 | 31 Dec 2018 | 001-11960 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIM | 27 Jun 2019 | 27 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTI | 19 Jun 2019 | 19 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVA | 19 Jun 2019 | 19 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFA | 19 Jun 2019 | 19 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN THE EU FOR 1ST-LINE | 18 Jun 2019 | 18 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENT | 17 Jun 2019 | 17 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | PUBLICATION OF A PROSPECTUS | 12 Jun 2019 | 12 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARY | 06 Jun 2019 | 06 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 03 Jun 2019 | 03 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Jun 2019 | 03 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROM | 03 Jun 2019 | 03 Jun 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE III | 10 May 2019 | 10 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 08 May 2019 | 08 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR DECLARATION | 08 May 2019 | 08 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLY | 08 May 2019 | 08 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINT | 07 May 2019 | 07 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETES | 03 May 2019 | 03 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 May 2019 | 01 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 01 May 2019 | 01 May 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1ST | 29 Apr 2019 | 29 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULT OF AGM | 26 Apr 2019 | 26 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: Q1 2019 RESULTS | 26 Apr 2019 | 26 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVE | 10 Apr 2019 | 10 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | HOLDING(S) IN COMPANY | 04 Apr 2019 | 04 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 03 Apr 2019 | 03 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Apr 2019 | 02 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Apr 2019 | 01 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATION | 01 Apr 2019 | 01 Apr 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | RESULTS OF PLACING | 29 Mar 2019 | 29 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVEL | 29 Mar 2019 | 29 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETES | 27 Mar 2019 | 27 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETES | 25 Mar 2019 | 25 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA GRANTS SARACATINIB ODD FOR IPF | 18 Mar 2019 | 18 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | NOTICE OF AGM | 14 Mar 2019 | 14 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | 6-K | 14 Mar 2019 | 14 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 12 Mar 2019 | 12 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FILING OF FORM 20-F WITH SEC | 06 Mar 2019 | 06 Mar 2019 | 001-11960 |
| IRANNOTICE | Open IRANNOTICE document | View SEC filing for IRANNOTICE | IRANNOTICE | 05 Mar 2019 | 001-11960 | |
| 20-F | Open 20-F document | Open XBRL data | View SEC filing for 20-F | 20-F | 05 Mar 2019 | 31 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ANNUAL FINANCIAL REPORT | 05 Mar 2019 | 05 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Mar 2019 | 01 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA RECEIVES POSITIVE EU CHMP OPINION | 01 Mar 2019 | 01 Mar 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA SIGNIFICANTLY DELAYED DISEASE PROGRESSION | 26 Feb 2019 | 26 Feb 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BRILINTA'S PHIII THEMIS TRIAL MET PRIMARY ENDPOINT | 25 Feb 2019 | 25 Feb 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA FULL-YEAR AND Q4 2018 RESULTS | 14 Feb 2019 | 14 Feb 2019 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | SEC SCHEDULE 13G | 12 Feb 2019 | 005-55247 | |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA GRANTS FASENRA ORPHAN DRUG DESIGNATION | 06 Feb 2019 | 06 Feb 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION | 05 Feb 2019 | 05 Feb 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | EMA GRANTS PRIME ELIGIBILITY FOR MEDI8897 | 05 Feb 2019 | 05 Feb 2019 | 001-11960 |
| SC 13G/A | Open SC 13G/A document | View SEC filing for SC 13G/A | 04 Feb 2019 | 005-55247 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Feb 2019 | 01 Feb 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FORXIGA RECEIVES POSITIVE EU CHMP OPINION | 01 Feb 2019 | 01 Feb 2019 | 001-11960 |
| SC 13G | Open SC 13G document | View SEC filing for SC 13G | SC 13G | 30 Jan 2019 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | COMPLETION OF DIVESTMENT OF US SYNAGIS RIGHTS | 25 Jan 2019 | 25 Jan 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA ANNOUNCES ORGANISATIONAL CHANGES | 07 Jan 2019 | 07 Jan 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 02 Jan 2019 | 02 Jan 2019 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BEVESPI AEROSPHERE APPROVED IN THE EU FOR COPD | 20 Dec 2018 | 20 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | LYNPARZA MEETS PRIMARY ENDPOINT IN SOLO-3 TRIAL | 20 Dec 2018 | 20 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | PHASE III ROCKIES AND OLYMPUS ROXADUSTAT TRIALS | 20 Dec 2018 | 20 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FDA APPROVES LYNPARZA AS 1L MAINTENANCE THERAPY | 19 Dec 2018 | 19 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISE | 18 Dec 2018 | 18 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTORATE CHANGE | 14 Dec 2018 | 14 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | UPDATE ON THE PHASE III EAGLE TRIAL OF IMFINZI | 07 Dec 2018 | 07 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIVESTMENT OF RIGHTS TO COVIS COMPLETED | 06 Dec 2018 | 06 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIRECTOR/PDMR SHAREHOLDING | 04 Dec 2018 | 04 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | BLOCK LISTING INTERIM REVIEW | 03 Dec 2018 | 03 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 03 Dec 2018 | 03 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | GRUNENTHAL AGREEMENT FOR NEXIUM VIMOVO COMPLETED | 03 Dec 2018 | 03 Dec 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA GRANTS FASENRA ODD FOR EGPA | 26 Nov 2018 | 26 Nov 2018 | 001-11960 |
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 16 Nov 2018 | 001-11960 | ||
| 25-NSE | Open 25-NSE document | View SEC filing for 25-NSE | 16 Nov 2018 | 001-11960 | ||
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA PROVIDES UPDATE ON PHASE III MYSTIC | 16 Nov 2018 | 16 Nov 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ASTRAZENECA TO DIVEST US SYNAGIS RIGHTS TO SOBI | 13 Nov 2018 | 13 Nov 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA | 13 Nov 2018 | 13 Nov 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | FARXIGA SIGNIFICANTLY REDUCED HOSPITALISATION FOR | 13 Nov 2018 | 13 Nov 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | AZN: YEAR-TO-DATE AND Q3 2018 RESULTS | 08 Nov 2018 | 08 Nov 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | DIVESTMENT OF RIGHTS TO COVIS PHARMA | 06 Nov 2018 | 06 Nov 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | TOTAL VOTING RIGHTS | 01 Nov 2018 | 01 Nov 2018 | 001-11960 |
| 6-K | Open 6-K document | View SEC filing for 6-K | ADDITIONAL FINANCIAL INFORMATION-GRUNENTHAL DEAL | 31 Oct 2018 | 31 Oct 2018 | 001-11960 |
About this filer
ASTRAZENECA PLC files with the SEC under CIK 0000901832. This page aggregates EDGAR filings and related ownership activity.
Industry: Pharmaceutical Preparations.
FAQ
- What is a CIK?
- A Central Index Key (CIK) is a unique identifier assigned by the SEC to each filer.
- Why are some filings missing?
- New filings appear as the SEC updates EDGAR, and older records can vary by availability.
- How often is this page updated?
- Updates follow new EDGAR submissions and periodic data refreshes.